Plumbagin Protects Diabetogenic Cataract Formation by Mitigating Lens Aldose Reductase and Oxidative Stress.

IF 1.8 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Pharmacopuncture Pub Date : 2025-09-30 DOI:10.3831/KPI.2025.28.3.191

Apurva Yadav, Rajesh Choudhary, Anshul Ram, Umashankar Nirmalkar, Swarnali Das Paul

{"title":"Plumbagin Protects Diabetogenic Cataract Formation by Mitigating Lens Aldose Reductase and Oxidative Stress.","authors":"Apurva Yadav, Rajesh Choudhary, Anshul Ram, Umashankar Nirmalkar, Swarnali Das Paul","doi":"10.3831/KPI.2025.28.3.191","DOIUrl":null,"url":null,"abstract":"Objectives: The polyol pathway plays an important pathophysiological role in diabetic-related ocular complications, including cataracts, one of the major causes of ocular blindness. The current paper investigated the protective effects of plumbagin against diabetogenic cataract formation, focusing on exploring its possible mechanism of action.Methods: The study investigates antioxidant activity, aldose reductase inhibitory activity, and anticataract activity in experimental pharmacological models. In the ex-vivo study, goat lenses were incubated in artificial aqueous humor with high concentrations of glucose (55.5 mM) and plumbagin (20, 50, and 100 µg/mL), which was assessed against cataract control lenses.Results: The in-vitro study showed that plumbagin inhibits 2,2-Diphenyl-1-Picrylhydrazyl free radical and lens aldose reductase activity. The ex-vivo study showed that plumbagin prevents lenticular opacity against the glucose-induced model. The plumbagin exposure significantly (p < 0.05) increased the antioxidant activity (catalase, superoxide dismutase and reduced glutathione) and reduced the malonaldehyde level. Moreover, plumbagin treatment significantly (p < 0.05) restored the lens protein content. Additionally, network pharmacological approaches suggested that SLC2A1, STAT3, and TP53 are the major target proteins for plumbagin in the prevention of cataract.Conclusion: The results concluded that plumbagin has promising anticataract activity by inhibiting lens aldose reductase and mitigating lenticular oxidative stress, making it a potential anticataract agent for diabetic conditions.","PeriodicalId":16769,"journal":{"name":"Journal of Pharmacopuncture","volume":"28 3","pages":"191-200"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464086/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacopuncture","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3831/KPI.2025.28.3.191","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The polyol pathway plays an important pathophysiological role in diabetic-related ocular complications, including cataracts, one of the major causes of ocular blindness. The current paper investigated the protective effects of plumbagin against diabetogenic cataract formation, focusing on exploring its possible mechanism of action.

Methods: The study investigates antioxidant activity, aldose reductase inhibitory activity, and anticataract activity in experimental pharmacological models. In the ex-vivo study, goat lenses were incubated in artificial aqueous humor with high concentrations of glucose (55.5 mM) and plumbagin (20, 50, and 100 µg/mL), which was assessed against cataract control lenses.

Results: The in-vitro study showed that plumbagin inhibits 2,2-Diphenyl-1-Picrylhydrazyl free radical and lens aldose reductase activity. The ex-vivo study showed that plumbagin prevents lenticular opacity against the glucose-induced model. The plumbagin exposure significantly (p < 0.05) increased the antioxidant activity (catalase, superoxide dismutase and reduced glutathione) and reduced the malonaldehyde level. Moreover, plumbagin treatment significantly (p < 0.05) restored the lens protein content. Additionally, network pharmacological approaches suggested that SLC2A1, STAT3, and TP53 are the major target proteins for plumbagin in the prevention of cataract.

Conclusion: The results concluded that plumbagin has promising anticataract activity by inhibiting lens aldose reductase and mitigating lenticular oxidative stress, making it a potential anticataract agent for diabetic conditions.

查看原文本刊更多论文

白桦素通过减轻晶状体醛糖还原酶和氧化应激保护糖尿病性白内障的形成。

目的：多元醇通路在糖尿病相关眼部并发症中起着重要的病理生理作用，包括白内障，这是眼致盲的主要原因之一。本文研究了白桦素对糖尿病性白内障形成的保护作用，重点探讨了其可能的作用机制。方法：在实验药理学模型中研究其抗氧化活性、醛糖还原酶抑制活性和抗白内障活性。在离体研究中，山羊晶状体在含有高浓度葡萄糖（55.5 mM）和白丹素（20、50和100µg/mL）的人工房水中孵育，并与白内障对照晶状体进行比较。结果：水杨桃苷对2,2-二苯基-1-苦酰基肼基自由基和晶状体醛糖还原酶活性有抑制作用。离体研究表明，白丹素可防止葡萄糖诱导的模型的透镜状混浊。水杨桃素显著（p < 0.05）提高了水杨桃抗氧化活性（过氧化氢酶、超氧化物歧化酶和还原性谷胱甘肽），降低了丙二醛水平。水杨桃素处理显著（p < 0.05）恢复了晶状体蛋白含量。此外，网络药理学方法提示SLC2A1、STAT3和TP53是白杨素预防白内障的主要靶蛋白。结论：白桦素具有抑制晶状体醛糖还原酶和减轻晶状体氧化应激的抗白内障活性，是治疗糖尿病的潜在抗白内障药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pharmacopuncture INTEGRATIVE & COMPLEMENTARY MEDICINE-

CiteScore

2.10

自引率

7.10%

发文量

审稿时长

10 weeks

期刊介绍： The Journal of Pharmacopuncture covers a wide range of basic and clinical science research relevant to all aspects of the biotechnology of integrated approaches using both pharmacology and acupuncture therapeutics, including research involving pharmacology, acupuncture studies and pharmacopuncture studies. The subjects are mainly divided into three categories: pharmacology (applied phytomedicine, plant sciences, pharmacology, toxicology, medicinal plants, traditional medicines, herbal medicine, Sasang constitutional medicine, herbal formulae, foods, agricultural technologies, naturopathy, etc.), acupuncture (acupressure, electroacupuncture, laser acupuncture, moxibustion, cupping, etc.), and pharmacopuncture (aqua-acupuncture, meridian pharmacopuncture, eight-principles pharmacopuncture, animal-based pharmacopuncture, mountain ginseng pharmacopuncture, bee venom therapy, needle embedding therapy, implant therapy, etc.). Other categories include chuna treatment, veterinary acupuncture and related animal studies, alternative medicines for treating cancer and cancer-related symptoms, etc. Broader topical coverage on the effects of acupuncture, the medical plants used in traditional and alternative medicine, pharmacological action and other related modalities, such as anthroposophy, homeopathy, ayurveda, bioelectromagnetic therapy, chiropractic, neural therapy and meditation, can be considered to be within the journal’s scope if based on acupoints and meridians. Submissions of original articles, review articles, systematic reviews, case reports, brief reports, opinions, commentaries, medical lectures, letters to the editor, photo-essays, technical notes, and book reviews are encouraged. Providing free access to the full text of all current and archived articles on its website (www.journal.ac), also searchable through a Google Scholar search.